medicina61巻3号

2024年03月発行

特集 どこでもみれる?—コモンディジーズとしての感染症アップデート 感染症新薬アップデートと感染症

イサブコナゾールの特徴—他の抗糸状菌作用を有するアゾール系抗真菌薬との違い

著者： 冲中敬二¹²

所属機関： ¹国立がん研究センター東病院感染症科 ²国立がん研究センター中央病院造血幹細胞移植科

ページ範囲：P.468 - P.472

Point
◎イサブコナゾール（ISCZ）はポサコナゾール（PSCZ）と同様にムーコル属をカバーする．
◎ISCZはボリコナゾール（VRCZ）やPSCZより肝機能障害などの副作用が少ないと報告されている．
◎ISCZはVRCZ，PSCZとの違いを理解したうえで処方する（臓器移行性，薬物相互作用，腎障害時の投与経路，経口吸収率など）．
◎ISCZは広いスペクトラムを有する抗真菌薬であり適正使用に注意する．

参考文献

1）Herbrecht R, et al：Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347：408-415, 2002 PMID 12167683

2）Pardo E, et al：Invasive pulmonary aspergillosis in critically ill patients with hematological malignancies. Intensive Care Med 45：1732-1741, 2019 PMID 31599334

3）Hoenigl M, et al：Global guideline for the diagnosis and management of rare mould infections；An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis 21：e246-e257, 2021 PMID 33606997

4）Maertens JA, et al：Posaconazole versus voriconazole for primary treatment of invasive aspergillosis；A phase 3, randomised, controlled, non-inferiority trial. Lancet 397：499-509, 2021 PMID 33549194

5）van Burik JA, et al：Posaconazole is effective as salvage therapy in zygomycosis；A retrospective summary of 91 cases. Clin Infect Dis 42：e61-65, 2006 PMID 16511748

6）Maertens JA, et al：Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi（SECURE）；A phase 3, randomised-controlled, non-inferiority trial. Lancet 387：760-769, 2016 PMID 26684607

7）Marty FM, et al：Isavuconazole treatment for mucormycosis；A single-arm open-label trial and case-control analysis. Lancet Infect Dis 16：828-837, 2016 PMID 26969258

8）Kullberg BJ, et al：Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections；The ACTIVE Trial. Clin Infect Dis 68：1981-1989, 2019 PMID 30289478

9）Ghez D, et al：Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 131：1955-1959, 2018 PMID 29437588

10）抗菌薬TDMガイドライン再改訂委員会：抗菌薬TDM臨床実践ガイドライン2022．日化療会誌70：1-72, 2022

11）Coussement J, et al：Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients. Curr Opin Infect Dis 34：297-306, 2021 PMID 34039878

12）Ullmann AJ, et al：Diagnosis and management of Aspergillus diseases；Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24 Suppl 1：e1-e38, 2018 PMID 29544767

13）Dadwal SS, et al：American Society of Transplantation and Cellular Therapy series, 2；Management and prevention of aspergillosis in hematopoietic cell transplantation recipients. Transplant Cell Ther 27：201-211, 2021 PMID 33781516

14）Nguyen MH, et al：Posaconazole serum drug levels associated with pseudohyperaldosteronism. Clin Infect Dis 70：2593-2598, 2020 PMID 31403165

15）Ji HH, et al：Antifungal therapy with azoles induced the syndrome of acquired apparent mineralocorticoid excess；A literature and database analysis. Antimicrob Agents Chemother 66：e0166821, 2022 PMID 34662186

16）Maertens JA, et al：European guidelines for primary antifungal prophylaxis in adult haematology patients；Summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73：3221-3230, 2018 PMID 30085172

17）Taplitz RA, et al：Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression；ASCO and IDSA clinical practice guideline update. J Clin Oncol 36：3043-3054, 2018 PMID 30179565

18）Nguyen MH, et al：Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases；Results from a subgroup analysis of a multicenter national registry. Open Forum Infect Dis 10：ofad424, 2023 PMID 37674634

19）Axell-House DB, et al：Breakthrough mucormycosis developing on mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer. J Fungi（Basel）7：217, 2021 PMID 33802827

20）Jenks JD, et al：Broad spectrum triazoles for invasive mould infections in adults；Which drug and when? Med Mycol 57（Supplement_2）：S168-S178, 2019 PMID 30816967